Biocon & Mylan launch Fulphila in Canada
Biocon, on Tuesday after market hours, announced the launch of Fulphila (biosimilar to pegfilgrastim) with Mylan in Canada.
Fulphila is approved by Health Canada to reduce the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
The company has expanded its portfolio with this after a successful launch in USA. This is Biocon’s second launch in Canada with Mylan.
Mylan and Biocon Biologics are exclusive partners on a broad portfolio of biosimilar and insulin products. Mylan has exclusive commercialisation rights for the product in US, Canada, Japan, Australia and New Zealand as well as in European Union and European Free Trade Association countries. Biocon has shared co-exclusive commercialisation rights with Mylan for the product in the rest of the world.
In today’s trading session, the stock of Biocon Limited witnessed gap up opening by 4 per cent at Rs 367 on the BSE.